Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Mometasone Furoate

The articles shown below are all about the Mometasone Furoate, through these related articles, you can get relevant information, notes in use, or latest trends about the Mometasone Furoate. We hope these news will give you the help you need. And if these Mometasone Furoate articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 13 2024

    Drug Patent & Exclusivity Expiration Report - Week of Jan 13 2024

    2025-01-13

    This week, there are 6 drugs in the patent and exclusivity list. They are: - BAUSCH AND LOMB INC's BEPREVE, containing active ingredient BEPOTASTINE BESILATE - ITALFARMACO SPA's DUVYZAT, containing active ingredient GIVINOSTAT HYDROCHLORIDE - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO & ENTRESTO SPRINKLE, containing active ingredient SACUBITRIL; VALSARTAN - GLENMARK SPECIALTY SA's RYALTRIS, containing active ingredient MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - ABBVIE INC's RINVOQ, containing active ingredient UPADACITINIB Read More